Food and Drug Administration (FDA) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Lasers in the management of alopecia: a review of established therapies and advances in treatment
AbstractAlopecia, also known as hair loss, is a highly prevalent condition affecting millions of men and women in the United States and worldwide, making it one of the most common complaints by patients presenting to a dermatologist. The symptomology on the presentation of alopecia can be highly variable, ranging from diffuse thinning of hair, discrete and localized patches completely absent of hair, or noticing significant shedding when brushing and showering. Although alopecia does not have a direct negative health impact on patients, it is nonetheless a debilitating disease as it can profoundly impact an individual ’s...
Source: Lasers in Medical Science - April 17, 2024 Category: Laser Surgery Source Type: research

Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval
J Korean Med Sci. 2024 Apr 15;39(14):e134. doi: 10.3346/jkms.2024.39.e134.ABSTRACTThe global research and pharmaceutical community rapidly mobilized to develop treatments for coronavirus disease 2019 (COVID-19). Existing treatments have been repurposed and new drugs have emerged. Here we summarize mechanisms and clinical trials of COVID-19 therapeutics approved or in development. Two reviewers, working independently, reviewed published data for approved COVID-19 vaccines and drugs, as well as developmental pipelines, using databases from the following organizations: United States Food and Drug Administration (US-FDA), Euro...
Source: J Korean Med Sci - April 16, 2024 Category: General Medicine Authors: Hee Sun Choi A Young Choi Jeffrey B Kopp Cheryl A Winkler Sung Kweon Cho Source Type: research

Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval
J Korean Med Sci. 2024 Apr 15;39(14):e134. doi: 10.3346/jkms.2024.39.e134.ABSTRACTThe global research and pharmaceutical community rapidly mobilized to develop treatments for coronavirus disease 2019 (COVID-19). Existing treatments have been repurposed and new drugs have emerged. Here we summarize mechanisms and clinical trials of COVID-19 therapeutics approved or in development. Two reviewers, working independently, reviewed published data for approved COVID-19 vaccines and drugs, as well as developmental pipelines, using databases from the following organizations: United States Food and Drug Administration (US-FDA), Euro...
Source: Journal of Korean Medical Science - April 16, 2024 Category: Biomedical Science Authors: Hee Sun Choi A Young Choi Jeffrey B Kopp Cheryl A Winkler Sung Kweon Cho Source Type: research

American College of Rheumatology (ACR) and Food and Drug Administration (FDA) Summit: Summary of the Meeting May 17 ‐18, 2022
On May 17-18, 2022, the ACR and the FDA co-sponsored a public meeting to address topics of mutual interest and importance in assessing long-term safety and clinical efficacy, as well as novel approaches to clinical trials in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). During the two-day consensus-building summit, rheumatologists, other health care professionals, and FDA staff provided a broad perspective on current clinical development challenges and potential approaches to address them. Key takeaways are summarized in this document, including issues related to innovative clinical trial designs, use of novel o...
Source: Arthritis and Rheumatology - April 16, 2024 Category: Rheumatology Authors: Jonathan Kay, Nikolay P. Nikolov, Michael H. Weisman, for the American College of Rheumatology Committee on Research Tags: Special Article Source Type: research

Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
AbstractAmong the most common molecular alterations detected in non-small-cell lung cancer (NSCLC) are mutations in Kristen Rat Sarcoma viral oncogene homolog (KRAS).KRAS mutant NSCLC is a heterogenous group of diseases, different from other oncogene-driven tumors in terms of biology and response to therapies. Despite efforts to develop drugs aimed at inhibitingKRAS or its signaling pathways,KRAS had remained undruggable for decades. The discovery of a small pocket in the binding switch II region ofKRASG12C has revolutionized the treatment ofKRASG12C-mutated NSCLC patients. Sotorasib and adagrasib, directKRASG12C inhibitor...
Source: Drugs - April 16, 2024 Category: Drugs & Pharmacology Source Type: research

Orexinergic Receptor Antagonists as a New Therapeutic Target to Overcome Limitations of Current Pharmacological Treatment of Insomnia Disorder
This study reviews the benefits and risks of current pharmacological treatments for insomnia, with special reference to the orexinergic system as a novel therapeutic target for treatment. The prescription of GABAergic mechanism enhancers (benzodiazepine (BZD) and "Z drugs") has shown efficacy in short-term insomnia treatment (less than 4 weeks), however, concerns arise regarding their long-term effectiveness, unfavorable tolerability and safety profiles, including the potential for dependency. Drugs with antihistamine properties, including certain antidepressants and antipsychotics, exhibit short-term efficacy but have doc...
Source: Actas Espanolas de Psiquiatria - April 15, 2024 Category: Psychiatry Authors: Cecilio Álamo Jer ónimo Sáiz Ruiz Cristina Zaragoz á Arnáez Source Type: research

Precision Medicine in the Era of Genetic Testing: Microsatellite Instability Evolved
Clin Colon Rectal Surg. 2023 Jul 25;37(3):157-171. doi: 10.1055/s-0043-1770385. eCollection 2024 May.ABSTRACTThe recognized importance of microsatellite instability (MSI) in cancer has evolved considerably in the past 30 years. From its beginnings as a molecular predictor for Lynch syndrome, MSI first transitioned to a universal screening test in all colorectal and endometrial cancers, substantially increasing the identification of patients with Lynch syndrome among cancer patients. More recently, MSI has been shown to be a powerful biomarker of response to immune checkpoint blockade therapy across a diversity of tumor typ...
Source: Clinical Colorectal Cancer - April 15, 2024 Category: Cancer & Oncology Authors: Dina Ioffe Michelle McSweeny Michael J Hall Source Type: research